PharmNXT Acquires Ireland’s DTR to Boost Bioprocess Capabilities in India

The acquisition also expands PharmNXT’s product portfolio and access to international markets.

PharmNXT Biotech has announced the acquisition of Defined Tubing Routing (DTR), an Ireland-based firm known for its modular bioprocess tubing systems. The move strengthens PharmNXT’s capabilities in engineering solutions for biopharmaceutical and pharmaceutical manufacturing, particularly in single-use technology setups.

The DTR systems, designed to manage volumes from 20 L to 500 L with custom spans up to 2.9 meters, help reduce operational risks, ensure proper flow path visibility, and support compliance in regulated environments. With this integration, PharmNXT will be positioned to offer enhanced customisation, faster turnaround, and better facility safety for pharma clients.

Sachin Joshi, Founder and Managing Director of PharmNXT, said, “This is a defining moment for the Indian biopharmaceutical sector. With this acquisition, PharmNXT will introduce innovative solutions for biopharmaceutical and pharmaceutical customers worldwide. DTR is an innovative solution to address issues related to single-use tubing management. DTR systems are designed to handle single-use tubing in pharmaceutical and biotech/biopharma facilities, ensuring proper routing, reducing errors, and enhancing the facility's overall appearance.”

The acquisition also expands PharmNXT’s product portfolio and access to international markets. Ankush Kapoor, Founder and CEO of PharmNXT Biotech, emphasized that the move aligns with the company’s manufacturing strategy. He said, “We are excited about this acquisition, which is highly strategic and complements our manufacturing capabilities in single-use technologies, consumables, and process equipment. The addition of DTR systems allows customers to access the full range of solutions in single-use technologies from PharmNXT. David Walton, the former owner of DTR, brings invaluable industry knowledge, further strengthening our technical leadership."

David Walton will now join PharmNXT as a strategic advisor. Highlighting the long-term value of the collaboration, he said, “Our combined strengths open up new possibilities in R&D and product customization, especially for clients operating in tightly regulated markets.”

The development comes as India’s pharmaceutical exports crossed $30 billion in FY25, with global companies increasingly viewing the country as a key supply chain partner due to its technical depth and regulatory adaptability.

Stay tuned for more such updates on Digital Health News